| Literature DB >> 33177049 |
Michael A van Es1, Steve Vucic2, Eva Maria Johanna de Boer1, Viyanti K Orie1, Timothy Williams3,4, Mark R Baker3,4,5, Hugo M De Oliveira3,4, Tuomo Polvikoski4,6, Matthew Silsby7, Parvathi Menon7, Mehdi van den Bos7, Glenda M Halliday8,9, Leonard H van den Berg1, Ludo Van Den Bosch10,11, Philip van Damme10,11,12, Matthew Kiernan8,9.
Abstract
Inclusions of pathogenic deposits containing TAR DNA-binding protein 43 (TDP-43) are evident in the brain and spinal cord of patients that present across a spectrum of neurodegenerative diseases. For instance, the majority of patients with sporadic amyotrophic lateral sclerosis (up to 97%) and a substantial proportion of patients with frontotemporal lobar degeneration (~45%) exhibit TDP-43 positive neuronal inclusions, suggesting a role for this protein in disease pathogenesis. In addition, TDP-43 inclusions are evident in familial ALS phenotypes linked to multiple gene mutations including the TDP-43 gene coding (TARDBP) and unrelated genes (eg, C9orf72). While TDP-43 is an essential RNA/DNA binding protein critical for RNA-related metabolism, determining the pathophysiological mechanisms through which TDP-43 mediates neurodegeneration appears complex, and unravelling these molecular processes seems critical for the development of effective therapies. This review highlights the key physiological functions of the TDP-43 protein, while considering an expanding spectrum of neurodegenerative diseases associated with pathogenic TDP-43 deposition, and dissecting key molecular pathways through which TDP-43 may mediate neurodegeneration. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: ALS; motor neuron disease; motor physiology
Year: 2020 PMID: 33177049 DOI: 10.1136/jnnp-2020-322983
Source DB: PubMed Journal: J Neurol Neurosurg Psychiatry ISSN: 0022-3050 Impact factor: 10.154